For a patient with well differentiated de novo triple positive metastatic breast cancer who did not respond to THP, do you sequence all available HER2 targeted options before endocrine therapy?
Endocrine combinations for triple positive breast cancer are honestly a bit understudied. We are starting to get more data in this space, SUMMIT, for example, neratinib + fulvestrant + trastuzumab. I think endocrine based combinations are very interesting and there are likely some tumors that are mo...
Triple-positive breast carcinoma (TPBC) is a subset of HR+/HER2+ tumors expressing both ER and PR. To date, only a few published reports have specifically studied TPBC and have focused on clinical outcomes in the adjuvant setting. (Vici et al., PMID 26910921) (You et al., PMID 30607163). In these st...
Whenever I hear well differentiated and HER2-positive in the same sentence, I must question whether this is a true HER2-positive disease.
About 10% of all breast cancers are ER+/HER2+ and half of those are also PR+, so triple-positive tumors account for only 5% of breast cancer.
The vast majority of t...
I agree with both Dr. @Dr. First Last and Dr. @Dr. First Last. However, this particular triple positive intrinsic subtype has presented itself as not HER2 responsive. Hence making me suspect a more endocrine-dominant biology. NGS and ESR evaluation with Mamaprint/blueprint subtyping albeit data is s...
Depends on the age, medical comorbidities, and extent of disease